-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MLBGmGGBsd2+jFrItHvdDiD9vYbVNFkqjlgPtZlyIPyXVIwvPtOUz2/Ow/niEjTh
 9i25dul1uuuEaH12kVOpEg==

<SEC-DOCUMENT>0001075880-08-000039.txt : 20080513
<SEC-HEADER>0001075880-08-000039.hdr.sgml : 20080513
<ACCEPTANCE-DATETIME>20080512213330
ACCESSION NUMBER:		0001075880-08-000039
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080509
FILED AS OF DATE:		20080513
DATE AS OF CHANGE:		20080512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		08825618

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20080509.htm
<DESCRIPTION>FORM 6K 2008 05 09
<TEXT>
<html>
  <head>
    <title>form6k20080509.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.5.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of May 2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
9 May, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR" style="TEXT-ALIGN: right">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
      <div style="TEXT-ALIGN: right">&#160;</div>
      <div style="MARGIN-LEFT: 27pt; TEXT-ALIGN: right">&#160;</div>
      <div><img src="novogenletterhead.jpg" alt="Novogen logo"></div>
      <div>&#160;</div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">9
MAY, 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">EXTENDED
ACCRUAL TIME AND DECREASED SAMPLE SIZE FOR OVATURE, A MULTINATIONAL PHASE III
CLINICAL STUDY FOR WOMEN WITH RECURRENT OVARIAN CANCER</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited&#8217;s subsidiary, Marshall Edwards Inc., (NASDAQ: MSHL), has made the
following announcement:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Sydney,
Australia; London, UK and New Canaan, Connecticut.&#160;&#160;&#160;The accrual
time for the <font style="DISPLAY: inline; FONT-WEIGHT: bold">OVA</font>rian
<font style="DISPLAY: inline; FONT-WEIGHT: bold">TU</font>mor <font style="DISPLAY: inline; FONT-WEIGHT: bold">RE</font>sponse (OVATURE) clinical
study, a Phase III study of the investigational chemosensitising drug,
phenoxodiol, has been extended to facilitate complete patient enrolment in the
US, Europe, and Australia.&#160;&#160;Increasing the accrual period allowed
decreasing the total number of patients in the study, without changing the
required statistical analyses.&#160;&#160;As a result, the OVATURE study will
enrol 340 patients at 60 &#8211; 80 clinical sites throughout the United States,
Europe, and Australia.&#160;&#160;Initially, this study was announced to enrol
470 patients.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
primary outcome of the OVATURE trial is the assessment of the relative time it
takes for the ovarian cancer to progress.&#160;&#160;The OVATURE trial design
has been approved by the US Food and Drug Administration (FDA) under a Special
Protocol Assessment (SPA) program, and provides for an interim analysis of the
data, which, if statistically significant, can be used to support a request for
accelerated marketing approval.&#160;&#160;An analysis of interim results will
be possible after patient recruitment to this study is completed and 95 patients
have disease progression.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is being developed by the US oncology company Marshall Edwards, Inc. (NASDAQ:
MSHL) as a novel therapeutic in combination with carboplatin for late-stage
chemoresistant ovarian cancers, as well as a monotherapy for prostate and
cervical cancers.&#160;&#160;Phenoxodiol is an investigational novel-acting drug
that inhibits key pro-survival signalling pathways operating within cancer cells
causing selective cancer cell death and increased susceptibility to drugs like
platinum and taxane, to which most ovarian cancer patients become resistant in
late stage disease.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
OVATURE trial is a major multi-centre multinational Phase III clinical trial of
orally-administered phenoxodiol in combination with carboplatin in women with
advanced ovarian cancer resistant or refractory to platinum-based drugs, to
determine its safety and effectiveness when used in combination with
carboplatin.&#160;&#160;The OVATURE trial is recruiting ovarian cancer patients
whose cancer initially responded to chemotherapy, but has since become resistant
or refractory to traditional platinum treatments.&#160;&#160;Patients are being
recruited at clinical sites across USA, UK, Europe and
Australia.&#160;&#160;Currently, more than 25 sites in the US, 20 sites in
Europe/UK, and five sites in Australia are participating in this clinical
study.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Patients
and caregivers who are interested in learning more about the OVATURE trial
should visit a website for this study at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.OVATUREtrial.com</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
phenoxodiol:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is being developed as a chemosensitising agent in combination with platinum
drugs for late stage, chemoresistant ovarian cancer and as a monotherapy for
prostate and cervical cancers.&#160;&#160;It has a unique mechanism of action,
binding to cancer cells via a cell membrane oxidase, causing major downstream
disturbances in expression of proteins necessary for cancer cell survival and
responsible for the development of drug resistance.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">In cancer
cells, phenoxodiol appears to selectively inhibit the regulator known as S-1-P
(sphingosine-1-phosphate) that is over expressed in cancer cells.&#160;&#160;In
response to phenoxodiol, the S-1-P content in cancer cells is decreased, with a
consequent decrease in expression of the pro-survival proteins XIAP and FLIP,
rendering those cells more sensitive to chemotherapy.&#160;&#160;Indeed, in
laboratory studies, it has been demonstrated that drug-resistant ovarian cancer
cells pre-treated with phenoxodiol were killed with lower doses of chemotherapy
drugs.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Importantly,
phenoxodiol has been shown not to adversely affect normal cells in animal and
laboratory testing.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is being investigated as a therapy for late-stage, chemoresistant ovarian,
prostate and cervical cancers.&#160;&#160;Phenoxodiol has received Fast Track
status from the FDA to facilitate its development as a therapy for recurrent
ovarian and prostate cancers.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is an investigational drug and, as such, is not commercially
available.&#160;&#160;Under US law, a new drug cannot be marketed until it has
been investigated in clinical trials and approved by FDA as being safe and
effective for the intended use.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is the first of a family of compounds in the Marshall Edwards, Inc.&#8217; drug
pipeline of flavanoid derivatives.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Marshall Edwards, Inc:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc. (NASDAQ: MSHL) is a specialist oncology company focused on the
clinical development of novel anti-cancer therapeutics.&#160;&#160;These derive
from a flavonoid technology platform, which has generated a number of novel
compounds characterized by broad ranging activity against a range of cancer cell
types with few side effects.&#160;&#160;The combination of anti-tumour cell
activity and low toxicity is believed to be a result of the ability of these
compounds to target an enzyme present in the cell membrane of cancer cells,
thereby inhibiting the production of pro-survival proteins within the
cell.&#160;&#160;Marshall Edwards, Inc. has licensed rights from Novogen Limited
(NASDAQ: NVGN) to bring three oncology drugs &#8211; phenoxodiol, triphendiol and
NV-143 &#8211; to market globally.&#160;&#160;The Company's lead investigational drug,
phenoxodiol, is in a Phase III multinational multi-centred clinical trial for
patients with recurrent ovarian cancer.&#160;&#160;More information on the trial
can be found at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.OVATUREtrial.com</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company
that is specializing in the development of therapeutics based on a flavonoid
technology platform.&#160;&#160;Novogen, based in Sydney, Australia, is
developing a range of therapeutics across the fields of oncology, cardiovascular
disease and inflammatory diseases.&#160;&#160;More information on phenoxodiol
and on the Novogen group of companies can be found at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.marshalledwardsinc.com</font>&#160;&#160;and
<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.novogen.com</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Under
US law, a new drug cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for the intended use.
Statements included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. You should be aware
that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenletterhead.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenletterhead.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!E`/P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`JM!<QRW=U`I^>%EW#ZJ"*LUYWJ?B>/PW\6UM[QQ'8ZE8PH
M[MP$D#N$8GTY(/U!/2FE<SJ34+-GHE%%%(T"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHK.UG7-/T"S6[U*8PP,XC#!"WS$$@8
M`/H:&[;CC%R=HJ[-&BL_1]<T[7[,W>FW`GA5RC':5(8=B#SW'YUH4)WV"47%
MVDK,**R;KQ)I=EKEOHT]P5OK@`QQ^6QR#G'.,=C6M233'*$HV;6X457O;ZUT
MZU>YO;B*W@3[TDC!0/SKDI_BIX7AE*+/<2C^\D#8_7%)RBMV73H5:GP1;.UK
MQ'XX6I77-*NC]V6V:/\`[Y;/_L]>I:+XOT/Q`_E6%\C3XSY,@*/^`/7\,UQW
MQKTXW'AJROU4DVESM8^BN,']0M:4I+F31QX^E*-*49*S10^&'Q#\[R/#VLS?
MO>$L[AS]_P!(V/KZ'OTZXSZY7Q_].#7T)\,?&;>)=(:QOI-VIV:@.Q/,T?0/
M]>Q]\'O6E6%M4<N"Q/-^[GOT.\HHK+UOQ%I?AV"*;5+GR4E8JF$9B3C/0`U@
MVEJSTXQE-\L5=FI138W$D:N`0&`(##!_$=JY_6/''A[0YF@N[]6N%.&BA4R,
MOUQP/H:&TM6.%.<WRP5V=%17&6OQ2\+W,H1KF>#)QNEA('YC.*Z^WN(;J!)[
M>:.:%QE)(V#*P]B*2DGLRJE&I3^.+1)114%Y>VNGVS7-Y<16\"?>DE8*!^)J
MC-)MV1/17%W'Q2\+P2%%N9Y@#C='`V/UQ5O3_B)X8U&80IJ(AD8X`N$,8/XG
MC]:CVD>YN\)72NX/[CJ:**YS4_'7A[1]1FL+V]:.YAQO40NV,@$<@8Z$53:6
MYE"G.H[05WY'1T5R/_"S/"G_`$$7_P#`>3_XFMO1/$&F^(;>6?3)S-'$^QR4
M9<'`/<#L:2G%Z)ESP]6"YI1:7H:=%8>M^+M%\/7,=OJ=TT,LB>8H$3-D9QV!
M]*U[:YAO+6*YMY%D@E0/&Z]&4C(-.Z;L0Z<XQ4FM&2T45D:9XGTG5]2NM/LK
MDR7-J6$J&-EVX;:>2,'FBZ0E"4DVEL:]%%%,D*X'XN_\BA!_U^I_Z"]=]7`_
M%W_D4(/^OU/_`$%ZBK\#.O`_[S#U.1\-7T_@37=.DN7/]D:Q:0RL[=%W*#GZ
MJQ(/^R<^E>V=1D5PUQX:3Q/\+]*M5"B[CL89+9SV<1CC/H1P?S[5'\,_$KZA
MIKZ)?%EO]/&T!^&:,''/NI^4_A44_=?+T9T8M*O%UE\479_HS,\3?\EGT'_K
ME%_Z%)7ILLJ00O+*P2-%+,QZ`#DFO,O$W_)9]!_ZY1?^A25UOCV=[?P-JSH2
M"8?+X]&8*?T)IQ=N9DUX<_L8=TE^)YU;QW_Q4\5R/-+)!H]H<A1_`AZ`#IO;
M!))Z<^@%>G67A'P_I]L((-(M"H')DB$C-]6;)-8'PHMHX?!@F4#?<7$CN?H=
MH_1:[FBG%6YGNQ8VO)5'2AI&.ECS3QI\.[9+1]7\/Q&UN[;]ZT$1(#`<Y3^Z
MPZC'7ZU/H.I'XA^`-2TF\93J"1>4SG@,>L<GYKS[J?6O1*\D\`QC3OB=K>GP
M\0!9U`]`L@V_D"12:Y)IKJ.,OK.&G"IJXZI^75'CDL4D$KPS(4EC8HZ,,%6!
MP0?QK6\+:[)X;\266IH3LC?$RC^*,\,/RY'N!7<?%WP>]CJ!\1646;2Y(%T%
M'^KEZ!OHW\_K7E]>DFI(^,J0E0J6['U\CK)&LB,&1@"K`\$'O7F'B,?\)5\5
M=.T8?/::<`\P[9X=OSPBUN^`M>CE^&=K?W3Y%A`\<I]!%D#_`,="UE_"NSEO
M&U;Q+=C]_>SLBGVSN?'MD@?\!KSZJ]Y0/K<#*U*6(\K+U?\`DBS\3/%EQH]I
M#I.G.R7UXN6=/O1QYQ\O^TQR`?8]\&E\(_#73]-LX[G6+>.[U!QN9)/FCB]@
M.A/J3GGI6%?QC4?CM!!/S'"Z%1_N0^8/_'J];J8KGDY/H;UIO#T84J>G,KM^
MI@ZGX+\/:K;&&;2[>,X^62!!&Z^X(_D<BO.=+N[_`.&OC$:3>3F72;E@=Q^[
MM8X$@'8@C##T'T->R5YI\9+6-]&TVZ(_>)<-$#_LLI)_]!%%6-ES+="P-9SG
M["H[QE^'FCT>XN(K6VEN)W"11(7=CV4#)/Y5X_8VVH?%3Q'+=7LLEOHUHV%C
M0_=!Z*.V\CDMV_*NI\57\Q^$0N"Q,MQ:6X=NA.\H&_/)_.KGPRMH[?P)9.@&
MZ=Y)7/J=Y'\E`_"B7OR4>FXZ/^ST)55\5^5>7<U+/P?X=L81'#HUF0!C=)$)
M&/U+9)JI?_#_`,,Z@Z.VF1P.KALV_P"[#8.<$#@@]#Q^5=-2,RK]Y@/J:TY(
M[6.-8BJGS*3OZB@8&!TKRAK&TU'XX7UM>VT5Q`8P3'*H921"F.#7J]>-:QK+
MZ#\8-0OX[*2\9451#&<$YA3GH>GTJ*ME:_<ZLO4I2J*._*_T/2O^$/\`#?\`
MT`M/_P#`=?\`"M#3]+L-*B>/3[."U1VW,L*!03C&3BN!_P"%J7G_`$*=]_WV
MW_Q%>@:==&^TRTO&B:%IX4E,3=4+`'!^F<547!_"8UZ>(IK][L_._P"IY?\`
M$NS74?'>A6+N46YC2(N!DJ&D(S^M7/ASK%QI&IW7@[53LF@=C;9[]V4>Q'SC
MV)]JC\=_\E-\,?[T/_HZKOQ-\/RM##XFTW,=]8$&5DZE`<AOJI_0GTK&S4G)
M=#T5*,Z-.A/:2T\G?0]$KRKX=?\`)0O$G^]-_P"CC7=^%?$$/B708+^/"R_<
MGC'\$@ZCZ=Q[$5PGPZ_Y*%XD_P!Z;_T<:N33<6CEH0E"E6C+=)?F>JT445L>
M<%<#\7?^10@_Z_4_]!>N^KC?B9I5_J_AF&WT^UDN9A=HY1,9"A6&>?J*BI\+
M.K!-1Q$&^YM>$_\`D3]%_P"O&'_T`5PGCW3+GPQXCM?&&E)\ID`N4'`W].?9
MAP??!ZFO0/#EO-:>&-*MKB,QS16D22(W56"`$5:U&PM]4TZ>QNTWP3H4<>Q[
MCW'44G'FC8JG7]E7<MT[W\T>6ZEJ5OJ_Q3\,ZA:-N@N+>)USU'S29!]P<@_2
MO1_$>FMK'AS4-/3_`%D\#*G./FQE?U`KR30_">M:/\0+&.:QNI;:UNL"Z6)C
M&4P2&ST'7\#FO;ZFE=IW-\<XTY4_9N]EI]YYC\(];3[)=:#<-LN(I#-$C<$J
M<!E^H(S^/M7IU>>>+_A_<W6I_P!N^')A;ZB&\QXMVS>W]Y3V8]P>#[<YI1>-
MO&^GH;>_\*RW,ZC`E2%P"?4[05/X8HC)P7+(*U&.*E[6BU=[INS3/1-5U.VT
M?2[C4+MML,"%F]3Z`>Y.`/K7FOPHM+B_UG5_$-PN/,)C!QP7=M[X^GR_G44N
MA^,_'MU$VLK_`&9IR-N$97;CW"$Y+>[8QSCTKT[2=*M-%TR#3[*/9!"N!DY)
M/<D]R3S0KSDGT1,N3#494T[SEO;HB>ZM8+ZTEM;J))8)5*21N,A@>H-?.WCW
MP)<>$;[SH-TNDSMB&4\F,_W&]_0]_P`Z^CZJZCIUKJVG3V%[$LMM.A1T/IZ^
MQ'4'L173";BSQL1AXUHVZGSYHFOO;_#S4="B.9[N_3:@/)0J,X_%%'_`C7O7
MA[2ET3P_8Z:N"8(@KD?Q/U8_B237D7A'P+>:?\3'LKJ&5K/3W^T+.4(64#F/
MGIG)4D>Q%>X5$E^\<CJHSM@J=+KJWZW:7X(\B\=>;X:^)&G^(0C&"78[%>Y4
M;'7Z[,?G7K%M<0WEM%<V\BR0RJ'1UZ,IY!K/\0Z!9^)-)DL+P$`G='(OWHW'
M1A_GD$UYS:6GCKP$SV]G:C5=-W$JJ*9`,]PH.Y3ZCD?7K6.L)-]&>A[N*I1C
M=*<=->J/6Z\D^*>I'6-:T_PW8'S9D<%P#QYK\*OX`DG_`'JLW/B[QWK*&UTS
MPW-8LXP9GC;(^C.%4?CFMCP3X!.A7!U7595N=4?)&"66+=U.3RS')R?<_4DF
MZGNQV*HTXX1^UJM<RV2=]?,V]>T#[;X)N-$M^66V6.'/=D`*_JHKD_A-K\3Z
M=+H$[;+F!VDA5N"R$Y8?4-G/U]C7I=>>>+_AY+?:@=;\/S_9M1W>8\>[8';^
M\K#[K?H?;G+G%IJ43+#U83A*A5=D]4^S/0Z\T^,P!T/3<_\`/RW_`*`:JP>+
M_'VD@6VH>'9+QDX\P6[Y;_@294_@*S]=_P"$T\>106TGATVD,,A=2ZM%R1CD
MN1D8]!4SFI1:2U-\+A94:T:DY+E76Z/7K/\`X\;?_KFO\J\WM/\`DO%[_P!<
MO_:*5Z7;HT5M%&V-RH%./4"O+M9L/$^G_$F^UW2-&:[0JJQL^-C`Q*I_B!Z@
MU539>IA@K.5172O%K7Y'JM%><?\`"3_$3_H5;?\`(_\`Q==+X4U/Q#J*79U_
M2X[`H5\D)_&#G/\`$>G'YU2FF[&-3"RIQYFU\FCD/'?_`"4WPQ_O0_\`HZO3
MW19$9'4,C##*PR"/0UP'C#1-3O\`Q]X?OK2RDFM;=HC+*N,)B7)SSZ<UZ#2@
MO>D:8F2=*DD]E^IY%:._PU\?-:RLPT34>58]$7/!^J$X/^R<^E6/AUQ\0O$O
M^]-_Z.-=EXU\-)XG\/R6R!1>1?O+9SV<?PY]"./R/:N,^%FD:KI^O7\VH:?>
M6RO;X#SQ,H9MP/4]36?*XS2Z'8JT*N&G-OW[)/SMLSU:BBBN@\8****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**IPZI:7-Z;2!Y)7",QD2
M)VB&URC+YH&S>&!!3.X8/%7*`"BBL_1-;T[Q'H\&K:3<?:+&?=Y<NQDW;6*G
MA@".01R*`-"BBB@`HHHH`**IWFJ6EC<6MO,\AGNGVQ1Q1/(QY`+$*"50%E!<
MX5=PR1D5<H`**S]*UO3M;^V_V=<>=]ANY+*X^1EV3)C<O(&<9'(R/>M"@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`KD_'>F:UJMOH<&C27:(NL6[Z@;6[-N
MWV3#"3+!E)'(X!STQTKK**`/"_"WA7XH1WNGCQ%J6LBW#QAO(O5E*PEY1+'*
MWVA,$JX;S%61U&S:5*;:Z#P[H'C>+6-%GU>;4GLYGMWO(GU(YM3;6AC^8*YW
MB:=MY"DC"*7R6(7U2B@#PM[WQ7=?%:;3=/UZ2>[:XU1D:"_$UK!$+=5MEEA4
MD1F.4X;?&,L>KFJ\7A/XH.;5)+WQ!Y0LKEI8VU%8@EU]FVQ[9%NG>0&55/S;
M5!)(50S`>^44`?/DWA7XP_V-,C:EK+:DR(B_9[V/RWCVQ':TC7"E'4HP+)'E
MCNR[A\CL_$FF>-;KQIIL&D65];Z%:2VUO+=IJK$W-L0PG+!IP0P#@!MC2$KN
M$@(45ZA10!\\>'_!/Q*TB/2+6"WU6TTRVB4:E:1:LB_:?]++N(-LN(V,97D&
M/[KC/S?-IZCX5^*D^CVZM?:E)?PZ%'&K6VJ^4/M?VO.&PZAG%N2"QR"1]YC@
MU[I10!XW\19O%=S\26TWPO/J37B:%%=VT%O>"*))5N\-(Z,ZHX*!EP0V=PXP
M,C#T'PC\1?#6GZ=9VVE7TMK+IYANX%UC:EM,;QG,B(MPF6\I5&$=`=YR>6!^
M@**`/"WT#XLR:9:3F;4AJ=IHZ)&%U)`K7:WN1O4/LD/V;J7!#=\M5B]T/XEV
M%^)]/MM2U""&]U*&*VEULHKVCH!;,Y\T,Q5GD8$GS/E`W+A"/;**`/'_``CH
M_P`0K?Q-#+XF35;C1(I9ELX(=15'@)EC9))\3EI(]N\;6DF(P1@C!.7;Z!\5
M;34M.N;F[UF\,6IQS:A#!=0K!<1)*[%HV:X!PRL!Y8CB0C;D97)]THH`^?-+
M\"_$BV\6^$=8G74C+&D4>KW$FK!V*"[=F0YD)9/*\L[5R#Z9S6W=Z5\15\+G
M35TW5;G6YI;A[S5EUG;&6!E\DV\:W$>U3O7(*JH"C,;D`#VBB@#P?3?#'Q'L
M/!L^;*^.NW&MSZA-;PWL4,-P'CC4F5XIHW7YB[*$;&5PRX*D>\444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
5%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
